Cytogenetics News and Research

RSS

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

NeoGenomics launches clinical molecular tests for comprehensive profiling of MDS

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome.

25 Jul 2013

Leica Biosystems announces acquisition of Kreatech Diagnostics

Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held provider of DNA fluorescent in-situ hybridization probes and target labeling reagents for microarrays.

9 Jul 2013

Transgenomic launches new mutation detection test for patients with metastatic colorectal cancer

Transgenomic, Inc. today announced the global, commercial availability of CRC RAScan, a new mutation detection test to screen patients with metastatic colorectal cancer for RAS mutations (KRAS and NRAS).

16 May 2013

Non-invasive prenatal genetic screening: an interview with Dr. Charles Strom, Senior Medical Director, Quest Diagnostics

A new category of non-invasive genetic screening tests is gaining a great deal of interest in the medical field – including from Quest Diagnostics -- for its potential to help screen women during pregnancy for genetic abnormalities known as trisomies, the most common of which is Down syndrome.

From Quest Diagnostics 13 Mar 2013

Genetic testing expansion results in urgent need for national policy

The Royal College of Pathologists of Australasia (RCPA) has announced new findings from nationwide research on the country’s genetic testing. The RCPA was contracted in 2012 by the Department of Health and Ageing to conduct its second survey on genetic testing. The findings were analysed by spokesperson on genetic testing for the RCPA, Professor Graeme Suthers, and Dr Kym Mina, Genetic Pathologist and Project Officer for the survey.

22 Feb 2013

NeoGenomics launches FISH assay for surveillance of patients with Barrett's Esophagus

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today it has validated and launched a laboratory developed Fluorescent in Situ Hybridization assay for the surveillance of patients with Barrett's Esophagus.

17 Dec 2012

UNM study to understand why and how DNA repair mechanisms go awry in cancer cells

DNA, like houses and cars, needs ongoing maintenance. Rays of ultraviolet sunlight, chemical pollutants and normal biochemical processes in the cell can damage it. Cells routinely repair this damage before making proteins or copying DNA for cell division. The repairs are remarkably accurate in normal cells but cancer cells make far more mistakes in fixing their DNA.

11 Dec 2012

New prenatal genetic test results in more clinically relevant information

A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant information than the current standard method of prenatal testing.

6 Dec 2012

Studies provide first clues of balanced de novo chromosomal rearrangements

Whole genome sequencing of the DNA code of three prenatal samples provided a detailed map of the locations of their chromosomal abnormalities in 14 days, scientists reported today at the American Society of Human Genetics (ASHG) 2012 meeting in San Francisco.

8 Nov 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

NIH awards $100,000 STTR Phase I Grant to Transgenomic for pancreatic cancer research

Transgenomic, Inc. today announced it has been awarded a $100,000 Small Business Technology Transfer Program (STTR) Phase I Grant by the National Institutes of Health's National Center For Advancing Translational Sciences.

23 Aug 2012

Agilent awarded patent for comparative genomic hybridization methods

Agilent Technologies Inc. today announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.

20 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

MCW, Transgenomic partner to offer next-generation genetic testing services

Transgenomic, Inc. and the Medical College of Wisconsin today announced a collaboration agreement under which Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program. These services will initially include Transgenomic's NuclearMitome Test for mitochondrial disorders.

30 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

Transgenomic introduces ICE COLD-PCR mutation detection technology

Transgenomic, Inc. today announced the commercial launch of its ICE COLD-PCR mutation detection technology, a breakthrough technology enabling unmatched sensitivity and complete DNA mutation detection using the standard sequencing equipment already installed in laboratories around the world.

6 Jun 2012